Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

NCT ID: NCT01172054

Last Updated: 2012-07-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 292 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-07-31
• Study Completion Date: 2011-11-30

Brief Summary

This is a multicenter, escalating dose-ranging study to assess the safety, reactogenicity and immunogenicity of 3 different novel H1N1 influenza vaccine constructs delivered i.m. as a single dose vaccination on day 0.

Detailed Description

VAX128-01 is a first in human study of three inactivated recombinant novel H1N1 influenza vaccines, designated VAX128 A, B and C. The purpose of the study is to compare the safety and immunogenicity of the three vaccines through a range of doses and to select one of the vaccines for further testing in phase II studies. We plan to assess the safety and immunogenicity in a dose escalating study. The study will enroll up to 100 healthy young adults (18-49 years) and 100 healthy adults than age 65 years. We are including the older adults in this phase 1 study because we have found that the elderly tolerated a vaccine similar to one of the candidates, VAX128A, better than young adults, but required a higher vaccine dose to achieve a similar antibody response. Nevertheless, because we are testing two other constructs (VAX128B and C), we will be making the conservative assumptions that the safety and immunogenicity data coming from the young adults will not predict the results in the elderly. Therefore, we will begin the study in the young adults and after the first three dose levels have been tested we will begin testing in the older adults. In this study we plan to enroll up to 100 young adults and up to 100 adults 65 years and older. The young adults will be most likely enrolled at one clinical site and the older adults will be enrolled at another clinical site. We plan to enroll a cohort of 10 young adults and 10 older adults every week. Each cohort will consist of 3 subjects to receive one of the three vaccines (9 subjects total) and one subject in each cohort will receive placebo. Dosing for the next cohort will be based on a two day assessment period after vaccination. The main part of the study will be conducted over 28 days and there will be two follow up phone calls at 6 months and one year.

Conditions

Influenza

Keywords

influenza vaccine recombinant

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

VAX128

Novel H1N1 Influenza vaccine

Group Type: EXPERIMENTAL

VAX128

Intervention Type: BIOLOGICAL

one IM injection

Placebo

one IM injection

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

One IM injection

Interventions

VAX128

one IM injection

Intervention Type: BIOLOGICAL

Placebo

One IM injection

Intervention Type: BIOLOGICAL

Other Intervention Names

STF2.HA1 CA07

Eligibility Criteria

Inclusion Criteria

• Healthy male or female aged 18 - 49 years or >= 65 years
• Give written informed consent
• Females have a negative urine test for pregnancy before vaccination and use birth control during 28 day study period
• Willing to receive the unlicensed (VAX128) vaccine given as an i.m. injection
• Willing to provide multiple blood specimens collected by venipuncture

Exclusion Criteria

• Chronic illness that would interfere with the subject's participation in the study or interpretation of the study results.
• Impaired immune responsiveness
• Received drugs effecting the immunity
• Received or plan to receive a nonstudy vaccine within 30 days prior to vaccination and during the study, including licensed influenza vaccines.
• History of anaphylactic type reaction to injected vaccines.
• History of drug abuse in the year prior to screening.
• History of Guillain-Barré Syndrome.
• Receipt or donation of blood products
• Acute disease within 72 hours prior to vaccination
• History of heart or lung disease
• Has other conditions that might interfere with study objectives.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

VaxInnate Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David N Taylor, MD

Role: STUDY_DIRECTOR

VaxInnate Corporation

Locations

Miami Research Associates

Miami, Florida, United States

Johnson County Clin-Trials

Lenexa, Kansas, United States

Countries

United States

References

Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine. 2012 Aug 24;30(39):5761-9. doi: 10.1016/j.vaccine.2012.06.086. Epub 2012 Jul 11.

Reference Type: DERIVED

PMID: 22796139 (View on PubMed)

Other Identifiers

VAX128-01

Identifier Type: -

Identifier Source: org_study_id